[{"orgOrder":0,"company":"Medicom Healthcare","sponsor":"Famar","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2021","type":"Acquisition","leadProduct":"Bimatoprost","moa":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Medicom Healthcare","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Medicom Healthcare \/ Famar","highestDevelopmentStatusID":"12","companyTruncated":"Medicom Healthcare \/ Famar"}]

Find Clinical Drug Pipeline Developments & Deals by Medicom Healthcare

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Under the agreement, Medicom has acquired the ownership of the pharmaceutical dossier of Zimed (bimatoprost), a preservative free eye drop solution, which is already registered in the UK and 5 EU countries with plans to commercialise the asset globally.

                          Brand Name : Zimed

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          February 09, 2021

                          Lead Product(s) : Bimatoprost

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Approved

                          Sponsor : Famar

                          Deal Size : Undisclosed

                          Deal Type : Acquisition

                          blank